DuoGenic StemCells (ROCO:7607) EPS (Basic): NT$-0.83 (TTM As of Dec. 2025)


ROCO:7607 DuoGenic StemCells Corp ROCO:7607
25 GF Score
Price NT$13.75
GF Value NT$50.56
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is DuoGenic StemCells EPS (Basic)?

DuoGenic StemCells ROCO:7607 -2.48% 25 EPS (Basic) is NT$-0.83 as of Dec. 2025. GuruFocus rates ROCO:7607 with a GF Score™ of 25/100 and a GF Value™ of NT$50.56 (Significantly Undervalued). The stock has 2 warning signs investors should review.

DuoGenic StemCells's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was NT$-0.36. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.83.

DuoGenic StemCells's EPS (Diluted) for the six months ended in Dec. 2025 was NT$-0.36. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.83.

DuoGenic StemCells's EPS without NRI for the six months ended in Dec. 2025 was NT$-0.36. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.83.

During the past 3 years, the average EPS without NRI Growth Rate was 11.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, DuoGenic StemCells's highest 3-Year average EPS without NRI Growth Rate was 11.40% per year. The lowest was -32.90% per year. And the median was -10.75% per year.

DuoGenic StemCells  (ROCO:7607) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

DuoGenic StemCells EPS (Basic) Related Terms

DuoGenic StemCells EPS (Basic) Historical Data

* Premium members only.

The historical data trend for DuoGenic StemCells's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DuoGenic StemCells EPS (Basic) Chart

DuoGenic StemCells Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
-0.86 -1.18 -1.50 -2.02 -0.83

DuoGenic StemCells Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only -0.77 -1.06 -0.96 -0.47 -0.36
ROCO:7607
25GF Score
DuoGenic StemCells Corp ROCO:7607
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DuoGenic StemCells EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

DuoGenic StemCells's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-26.38-0)/31.918
=-0.83

DuoGenic StemCells's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-11.942-0)/32.988
=-0.36

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of NT$-0.83 mean?
DuoGenic StemCells (ROCO:7607) has a EPS (Basic) of NT$-0.83 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on DuoGenic StemCells and its competitors.
Is DuoGenic StemCells' EPS (Basic) too high?
DuoGenic StemCells' current EPS (Basic) is NT$-0.83. Overall, DuoGenic StemCells has a GF Score™ of 25/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' EPS (Basic) compare to VRTX and REGN?
DuoGenic StemCells' EPS (Basic) of NT$-0.83 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on DuoGenic StemCells and its competitors. DuoGenic StemCells's current EPS (Basic) is NT$-0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$50.56, compared to a current price of NT$13.75 — trading 72.8% below its estimated fair value. The current EPS (Basic) is NT$-0.83. DuoGenic StemCells' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current EPS (Basic) is NT$-0.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?

Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued. The current stock price of NT$13.75 is trading 72.8% below its estimated GF Value™ of NT$50.56. GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.

Key valuation signals for ROCO:7607:

  • EPS (Basic): NT$-0.83
  • GF Value™: NT$50.56 vs. price of NT$13.75 (72.8% below fair value)
  • GF Score™: 25/100 with 2 warning signs

No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DuoGenic StemCells Business Description

Address Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
25GF Score

Get the complete analysis for ROCO:7607

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$13.75
Price
NT$50.56
GF Value